Foghorn Therapeutics (FHTX) Equity Average: 2020-2025
Historic Equity Average for Foghorn Therapeutics (FHTX) over the last 6 years, with Sep 2025 value amounting to -$83.2 million.
- Foghorn Therapeutics' Equity Average fell 290.33% to -$83.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$83.2 million, marking a year-over-year decrease of 290.33%. This contributed to the annual value of -$61.4 million for FY2024, which is 59.21% down from last year.
- According to the latest figures from Q3 2025, Foghorn Therapeutics' Equity Average is -$83.2 million, which was down 20.25% from -$69.2 million recorded in Q2 2025.
- In the past 5 years, Foghorn Therapeutics' Equity Average ranged from a high of $135.7 million in Q1 2021 and a low of -$87.3 million during Q1 2024.
- In the last 3 years, Foghorn Therapeutics' Equity Average had a median value of -$53.6 million in 2025 and averaged -$52.5 million.
- As far as peak fluctuations go, Foghorn Therapeutics' Equity Average soared by 1,282.56% in 2021, and later tumbled by 650.76% in 2023.
- Quarterly analysis of 5 years shows Foghorn Therapeutics' Equity Average stood at $88.9 million in 2021, then crashed by 86.26% to $12.2 million in 2022, then tumbled by 650.76% to -$67.3 million in 2023, then spiked by 45.15% to -$36.9 million in 2024, then tumbled by 290.33% to -$83.2 million in 2025.
- Its last three reported values are -$83.2 million in Q3 2025, -$69.2 million for Q2 2025, and -$53.6 million during Q1 2025.